CHF Solutions Expands Intellectual Property Portfolio with Two New Patent Filings for Innovations to Aquadex FlexFlow® System

January 16, 2019 GMT

EDEN PRAIRIE, Minn., Jan. 16, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the filing of two new patent applications with the United States Patent and Trademark Office (USPTO) designed to deepen the company’s intellectual property protection for its Aquadex FlexFlow system.

“CHF Solutions has long remained dedicated to innovation of its technology and optimizing the application of our Aquadex FlexFlow system for the treatment of fluid overload in a variety of settings,” said John Erb, chairman and CEO of CHF Solutions. “The new innovative features contained in these pending patent applications reflect that dedication.”

One of the two applications is based on the company’s design for a wearable device designed to assist in maintaining peripheral venous blood flow access in the arm during aquapheresis treatment with the Aquadex FlexFlow system. The second application includes multiple potential new features and improvements to the diagnostic capabilities of the Aquadex FlexFlow system, which, if incorporated into the product, would be designed to help ensure optimal patient fluid balance and to dramatically improve usability for healthcare providers.


About CHF Solutions

CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company’s mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

Forward-Looking Statements


Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the ability of the design features contained in the patents to improve product performance. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


INVESTORS: Claudia Napal Drayton Chief Financial Officer CHF Solutions, Inc. 952-345-4205

-or- Bret Shapiro Managing Partner CORE IR 516-222-2560

MEDIA Jules Abraham JQA Partners, Inc. 917-885-7378